Statistics

Total Visits

Views
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study44

Select a period of time:

Number of views in the range

Views
Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: Results of a 12-week, phase II, dose-finding study31

Views

Views
January 20250
February 20253
March 202515
April 202512
May 20251
June 20250
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
Hong Kong10
United States5
Spain1
 

Top cities views

Views
Hong Kong10
Council Bluffs1
Kearny1
Seattle1